Vertex kidney drug povetacicept succeeds in trial for IgAN
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters…
These 4 charts show the scale of Novo Nordisk’s woes
Novo Nordisk was the first company to make a GLP-1 drug for weight loss and became Europe’s most…
The big market rotation may lead to gains in this health care name. Trading it with options
While the stock market rarely offers absolute certainties, historical seasonality is a rhythm that plays out more often…
Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion
A Gilead Sciences office is shown in Foster City, California, U.S. May 1, 2018. Stephen Lam | Reuters…
What’s likely to move the market in the next trading session
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
In unusual occurrence, both the Dow and small caps could be headed for a breakout, charts suggest
As we know, large-cap growth and technology have been breaking out from various bullish patterns over the last…